Business & Finance
Protein-focused bioscience company reports Q2 revenue of $7.5 million
Published in Drug Week, September 9th, 2005
Ciphergen's total revenue was $7.5 million in the second quarter of 2005 as compared to $8.3 million in the second quarter of 2004. Ciphergen's net loss was $9.0 million in the second quarter of 2005 as compared to $13.1 million in the second quarter of 2004.
As of June 30, 2005, the company's cash and investments were $23.5 million. Total long-term debt totaled $28.4 million, of which $28.3 million was convertible debt. On July 22, 2005, Ciphergen entered into a strategic alliance with Quest Diagnostics whereby Quest Diagnostics made a $15...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-09-09)
More Articles from Drug Week
- Cancer Therapy
Two additional sites initiated for phase II ADH-1 trial - Generic Drugs
U.S. FDA approves generic equivalent to topical suspension for fungal infections - HIV/AIDS Therapy
Company updates development of fixed-dose regimen of Truvada and Sustiva - Hemophilia
Data for Advate confirm safety and efficacy in hemophilia A patients - Kidney Disease
Phase III program for ferumoxytol modified in IV iron replacement therapy - Acetylcholine Receptors
Nicotinic receptors analyzed, regulatory roles defined - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
